NCT06643793View on ClinicalTrials.gov

Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Colorectal Neoplasms Malignant
Interventions
DRUG

Irinotecan liposome (ll) + 5-FU/LV + bevacizumab

"1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w."

Trial Locations (1)

025

RECRUITING

Affiliated Hospital Of Nantong University, Nanjing

All Listed Sponsors
lead

Affiliated Hospital of Nantong University

OTHER